Barriers to optimizing inflammatory bowel disease care in the United States.

IF 4.2 3区医学

Therapeutic Advances in Gastroenterology Pub Date : 2023-05-05 eCollection Date: 2023-01-01 DOI:10.1177/17562848231169652

Elizabeth A Spencer, Sadeea Abbasi, Maia Kayal

引用次数: 0

Abstract

Significant progress in the management and modification of inflammatory bowel disease (IBD) has been made; however, significant barriers to the optimization of IBD care in the United States still exist. The majority of these barriers are constructed by insurance carriers and the integration of market pressures into healthcare decision-making. In this review, we highlight the barriers to IBD care optimization within the context of the US insurance system and review current and proposed solutions.

Abstract Image

查看原文本刊更多论文

美国优化炎症性肠病护理的障碍。

美国在炎症性肠病（IBD）的管理和治疗方面取得了重大进展，但在优化 IBD 治疗方面仍然存在重大障碍。这些障碍大多是由保险公司以及将市场压力纳入医疗决策所造成的。在这篇综述中，我们强调了在美国保险体系背景下 IBD 护理优化所面临的障碍，并回顾了当前和拟议的解决方案。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Therapeutic Advances in Gastroenterology Medicine-Gastroenterology

自引率

2.40%

发文量

103

期刊介绍： Therapeutic Advances in Gastroenterology is an open access journal which delivers the highest quality peer-reviewed original research articles, reviews, and scholarly comment on pioneering efforts and innovative studies in the medical treatment of gastrointestinal and hepatic disorders. The journal has a strong clinical and pharmacological focus and is aimed at an international audience of clinicians and researchers in gastroenterology and related disciplines, providing an online forum for rapid dissemination of recent research and perspectives in this area. The editors welcome original research articles across all areas of gastroenterology and hepatology. The journal publishes original research articles and review articles primarily. Original research manuscripts may include laboratory, animal or human/clinical studies – all phases. Letters to the Editor and Case Reports will also be considered.